Day: October 7, 2022

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept for oral delivery of vaccines using Oravax technology NEW YORK , Oct.

Seeking Alpha: Oramed oral COVID vaccine shows promise in phase 1 trial

Oramed oral COVID vaccine shows promise in phase 1 trial | Seeking Alpha

  • +1-844-9-ORAMED
  • office@oramed.com
  • 1185 Avenue of the Americas, New York, NY 10036 USA
Linkedin-in Facebook-f Twitter Youtube

Copyright © 2022 Oramed. | Terms & Conditions | Privacy Statement | Cookie Policy

Join our mailing list

  • +1-844-9-ORAMED
  • office@oramed.com
Linkedin-in Facebook-f Twitter Youtube
Home
About
Technology
Pipeline
Video Library
Contact us
NEWS
Press Releases
In the News
Scientific Articles and Abstracts
Events & Presentations
INVESTORS
Corporate presentation
Investor Relations
SEC filings
Investor FAQ
Governance documents
Investor tools
Oravax Medical
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase Text Increase Text
  • Decrease Text Decrease Text
  • Grayscale Grayscale
  • High Contrast High Contrast
  • Negative Contrast Negative Contrast
  • Light Background Light Background
  • Links Underline Links Underline
  • Readable Font Readable Font
  • Reset Reset